Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20284937 | 1.00 | METAP1 (0.50) | METAP1NAMPTTDP2CYP17A1ATR | |
| SCHEMBL29919353 | 0.89 | METAP1 (0.52) | METAP1NAMPTTDP2CYP17A1ATR | |
| SCHEMBL22075675 | 0.89 | METAP1 (0.52) | METAP1NAMPTTDP2CYP17A1ATR | |
| SCHEMBL31561700 | 0.88 | METAP1 (0.51) | METAP1NAMPTTDP2CYP17A1ATR | |
| SCHEMBL31213811 | 0.86 | METAP1 (0.49) | METAP1NAMPTTDP2CYP17A1ATR | |
| SCHEMBL31561715 | 0.86 | METAP1 (0.49) | METAP1NAMPTTDP2CYP17A1ATR | |
| SCHEMBL23482029 | 0.85 | METAP1 (0.53) | METAP1NAMPTTDP2CYP17A1ATR | |
| SCHEMBL29619168 | 0.85 | METAP1 (0.53) | METAP1NAMPTTDP2CYP17A1ATR | |
| SCHEMBL2082187 | 0.85 | METAP1 (0.53) | METAP1NAMPTTDP2CYP17A1ATR | |
| SCHEMBL31561754 | 0.85 | METAP1 (0.48) | METAP1NAMPTTDP2CYP17A1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | METAP1 1236/4885NAMPT 719/4885TDP2 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.